US patent granted for 4SC's clinical Project

The Munich-based drug discovery and development company 4SC AG has been informed by the US Patent and Trademark Office (PTO) that the office has granted the patent with the US patent number 7,071,355.

This patent protects, apart from the composition of a group of DHODH inhibitors that are chemically related to 4SC's clinical drug candidate (SC12267), also their use as a medication to treat diseases, such as rheumatoid arthritis or cancer.

"This patent is of strategic significance for a potential licensing partnership related to our most advanced project and strengthens our position in the competitive environment around autoimmune diseases," commented Ulrich Dauer, CEO of 4SC AG. "Partners in the pharmaceutical industry consider a clear patent situation as crucial and the US is the most important pharmaceutical market in the world."

"This builds up our foundation of proprietary rights for our therapeutic pipeline," emphasises Daniel Vitt, CSO of 4SC AG and inventor of the company's technological platform. "The granting of the patent is another example of the outstanding performance of our technology." International patents equivalent to the US patent have also been applied for in other important markets, including Europe, Japan and Canada.

http://www.4sc.de